1. Generics Bulletin
  2. >>Business
  3. >>Deals

Piramal Snaps Up Peptide API Specialist Hemmo

Bolsters CDMO Business In Deal Worth More Than $100m

 
• By Dave Wallace

Piramal has announced a $106m deal to take full ownership of peptide API specialist Hemmo Pharmaceuticals, expanding its CDMO capabilities.

API Wooden Blocks Graphs
Piramal Pharma Solutions will gain peptide API capabilities from Hemmo • Source: Shutterstock

Piramal Pharma Limited has announced that it will bolster its Piramal Pharma Solutions contract development and manufacturing organization by acquiring peptide active pharmaceutical ingredient specialist Hemmo Pharmaceuticals “for an upfront consideration of INR7.75bn ($106m) and earn-outs linked to achievement of milestones.”

Noting that the acquisition, which is subject to customary regulatory closing conditions, would add peptide API development and manufacturing capabilities...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Alvotech Boosts Packaging Abilities With Ivers-Lee Acquisition

 
• By Dean Rudge

Alvotech has acquired long-time partner Ivers-Lee to expand its in-house capacity for assembly and packaging ahead of key planned biosimilar launches in 2025, strengthening operational control and supporting global growth.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By Dave Wallace

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By Dean Rudge

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.

Bio Usawa To Market Formycon’s Lucentis Biosimilar In Sub-Saharan Africa

 
• By Urtė Fultinavičiūtė

Bio Usawa’s CEO said access to advanced biologics should not be a privilege of geography or income, as it prepares to launch Formycon/Bioeq’s ranibizumab biosimilar in Africa.

More from Business

Bakers And Fishermen: How Biosimilars Manufacturers Are Bridging The Skills Gap

 
• By Dave Wallace

At Medicines for Europe’s annual conference in Brussels, executives from Polpharma Biologics and Gedeon Richter spoke about the challenges in finding biosimilars manufacturing staff with the right backgrounds – and how they are looking to other industries to bridge the skills gap.

Lupin And Zentiva Throw Hat Into The Ring On Biosimilar Cimzia

 
• By Dave Wallace

The announcement by Lupin and Zentiva of a development and commercialization deal on a certolizumab pegol biosimilar candidate has revealed a new potential challenger to Alvotech’s AVT10, previously thought to be the only Cimzia rival in development.

China’s Qilu Looks To US Hospitals Market With Sagent Injectables Collaboration

 
• By Dean Rudge

Sagent and Qilu will look to enhance access, reduce treatment costs, and strengthen supply chains after striking an alliance for a portfolio of the Chinese firm’s complex injectables.